StockpollyBeta
Get App
Popularity #2,586
SEPN · NASDAQ · Biotechnology

Septerna (SEPN)

Develops oral GPCR drug candidates using its Native Complex Platform.

$38.75
After-hours close+0.30 (+0.78%)
At close$38.45(−4.78%)

  1. VIRGINIA RETIREMENT SYSTEMS ET Al Buys Shares of 13,300 Septerna, Inc. $SEPN

    Defense World

  2. Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

    GlobeNewsWireLeadership

  3. Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates

    Zacks Investment Research

  4. Septerna's Chief People Officer Sold Nearly 12,000 Company Shares. What Does That Mean for Investors?

    The Motley Fool

  5. Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates

    Zacks Investment Research

  6. Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results

    GlobeNewsWire

  7. Septerna to Present at Bank of America Securities Health Care Conference

    GlobeNewsWire

  8. Septerna, Inc. (SEPN) Reports Q4 Loss, Tops Revenue Estimates

    Zacks Investment Research

  9. Septerna Highlights Pipeline Progress and Reports Fourth Quarter and Full Year 2025 Financial Results

    GlobeNewsWire

  10. Septerna Announces Positive Phase 1 Data for SEP-631, an Oral MRGPRX2 NAM for the Treatment of Mast Cell-Driven Diseases, and Outlines Initial Phase 2 Development Strategy

    GlobeNewsWire

  11. Septerna (NASDAQ:SEPN) Stock Price Down 5.9% on Insider Selling

    Defense World

  12. Septerna to Present Data from Phase 1 Clinical Trial of SEP-631 for the Treatment of Mast Cell-Driven Diseases at 2026 AAAAI Annual Meeting

    GlobeNewsWire

  13. Septerna Expands Leadership with Appointment of Industry Veteran Mark A. Wilson as Chief Legal Officer

    GlobeNewsWire

  14. Septerna's Novo Partnership Begins To Transform The Story

    Seeking Alpha

  15. Septerna, Inc. (SEPN) Reports Q3 Loss, Misses Revenue Estimates

    Zacks Investment Research

  16. Septerna Highlights Company Progress and Reports Third Quarter 2025 Financial Results

    GlobeNewsWire

  17. Septerna to Participate in Upcoming Investor Conferences

    GlobeNewsWire

  18. Strength Seen in Septerna, Inc. (SEPN): Can Its 7.0% Jump Turn into More Strength?

    Zacks Investment Research

  19. Septerna Appoints Veteran Biotechnology Leader Keith Gottesdiener, M.D., to its Board of Directors

    GlobeNewsWire

  20. Septerna Announces Dosing of the First Participants in Phase 1 Clinical Trial of SEP-631, an Oral Small Molecule MRGPRX2 Negative Allosteric Modulator for the Treatment of Mast Cell-Driven Diseases

    GlobeNewsWire

  21. Septerna Highlights Business Progress and Reports Second Quarter 2025 Financial Results

    GlobeNewsWire

  22. Analyst Flags Septerna As Undervalued Biotech Play With Significant Upside

    Benzinga

  23. Does Septerna, Inc. (SEPN) Have the Potential to Rally 151.27% as Wall Street Analysts Expect?

    Zacks Investment Research

  24. Septerna: Novo's Investment In Incretin Program Intrigues - One For The Watchlist

    Seeking Alpha